Mind Medicine (MindMed) Inc. (MNMD)

CA — Healthcare Sector
Peers: CYBN  SEEL  GHRS  AWKNF  ATAI  FRLN  BPTH  VCNX  ELYM  OPT  MOLN  EWTX  ITOS  CKPT  MBIO  RVPH  FBIOP  KOD 

Automate Your Wheel Strategy on MNMD

With Tiblio's Option Bot, you can configure your own wheel strategy including MNMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MNMD
  • Rev/Share 0.0
  • Book/Share 2.6192
  • PB 2.9361
  • Debt/Equity 0.0989
  • CurrentRatio 7.2734
  • ROIC -0.4651

 

  • MktCap 581004646.0
  • FreeCF/Share -1.0779
  • PFCF -6.3365
  • PE -8.4271
  • Debt/Assets 0.08
  • DivYield 0
  • ROE -0.3344

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation MNMD Evercore ISI -- Outperform -- $23 Jan. 28, 2025
Initiation MNMD Chardan Capital Markets -- Buy -- $20 Dec. 20, 2024
Resumed MNMD Leerink Partners -- Outperform -- $20 Oct. 14, 2024

News

Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade
MNMD
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 237.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?
MNMD
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 279.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?
Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript
MNMD
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - Chief Executive Officer Matt Wiley - Chief Commercial Officer Dan Karlin - Chief Medical Officer Conference Call Participants Madhu Yennawar - Leerink Partners Brian Abrahams - RBC Capital Markets Elaine Kim - Cantor Rudy Li - Chardan Sumant Kulkarni - Canaccord Genuity Michael Okunewitch - Maxim Group Operator Good morning, and welcome to the MindMed's First Quarter 2025 Financial Results and Corporate Update Webcast. Currently, all participants are in listen-only mode.

Read More
image for news Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript
Why Mind Medicine Stock Is Skyrocketing Today
MNMD
Published: February 14, 2025 by: The Motley Fool
Sentiment: Positive

Mind Medicine (MNMD 15.66%) stock is seeing impressive gains Friday. The company's share price was up 16.9% as of 3:15 p.m.

Read More
image for news Why Mind Medicine Stock Is Skyrocketing Today

About Mind Medicine (MindMed) Inc. (MNMD)

  • IPO Date 2016-11-15
  • Website https://www.mindmed.co
  • Industry Biotechnology
  • CEO Mr. Robert Barrow
  • Employees 74

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.